Authors
Latest:
Protecting pharmaceutical exclusivity: Avoiding the hidden dangers of double patentingMultiple patents contribute to a robust portfolio; however, each patent that issues can potentially become a landmine to another
Latest:
Manufacturers can support the ICD-10 transitionHealthcare's conversion to a new coding system can affect drug prescribing. Here's what you need to know
Latest:
Monetizing Intellectual Property: Royalties, Revenues and Alternative Sources of CapitalInvestment funds have developed an interest in trading capital for royalties on drug commercializations
Latest:
Active packaging protects oral solid formulationsNew technologies offer improved shelf life for moisture- and oxygen-sensitive oral solids
Latest:
The Truth Behind IDNs: Is It Who You Know, or What You Know?Connecting with buying influences in integrated delivery networks is a challenge
Latest:
The Drive to Develop New Commercial ModelsIndustry’s coming challenges will force dramatic change on how products are brought to market and businesses are sustained. Industry leaders have already started the process
Latest:
REMS Drives Manufacturer-Specialty Pharmacy RelationshipsSpecialty pharmacies are competing to position themselves as the best partners for manufacturers dealing with high-touch, high-risk products
Latest:
Pharma in China--calculated risk gone wrongDoing business in China is undergoing important changes
Latest:
AstraZeneca's Principles for Product-Related Online CommunicationsIndustry anticipates meaningful guidance from FDA on use of social media
Latest:
Cloud-based services manage regulated content betterUnifying the management of clinical research documentation and marketing content saves time and accelerates speed-to-therapy
Latest:
Pharma's stake in comparative effectiveness researchWhen drugs in development today hit the marketplace in 2020, they will need evidence of economic and clinical value results to be commercially successful
Latest:
Follow the Money... Where Healthcare Policy is HeadedCMS will be changing reimbursement practices regardless of how healthcare reform plays out
Latest:
Pharma pricing and antitrust lawUS courts fail to clarify when pricing may violate antitrust laws
Latest:
The Evolving Retail Pharmacy Channel: Implications for ManufacturersAggressive cost competition and the continuing growth of generic substitution will separate retailers’ interests from manufacturers’
Latest:
Air Cargo Logistics: Critical Collaboration Points, Sustainability and Thermal PackagingAlison Crawley and Bourji Mourad, Sonoco ThermoSafe, react to lessons learned from the 2024 LogiPharma Masterclass and consider the future of sustainable thermal packaging as it relates to air cargo logistics.
Latest:
Specialty Pharmaceuticals and the Emergence of Sub-Specialty Pharmacy‘Ultra-orphan’ diseases will alter the specialty distribution process
Latest:
Drug shortages are opening the door to price gougingHospital pharmacies need to be vigilant in ensuring safe supplies of scarce drugs
Latest:
Is tech running you? Four ways to retake controlModern training technologies make the prospect of days-long training courses an obsolete practice
Latest:
The clear and present danger of counterfeit drugsProspects for international policing of counterfeit drugs is dim
Latest:
Industry should reinforce cargo security practices with TAPA participationUltimately, supply chain integrity should include both temperature control and security against theft or diversion
Latest:
The right supply chain prescriptionWhile pharma manufacturers may be concerned about the impact of item-level inventory tracking, it's an idea that actually makes great business sense
Latest:
The convergence of international and US pricing controlsNew approaches, and new skill sets are necessary for meeting the challenges of global drug reimbursement policies
Latest:
Common misconceptions about the orphan drug designationThings to know about the increasingly popular--and competitive--orphan drug space
Latest:
Building an Alternative Distribution Model for Ultra-Orphan DiseasesBiopharmaceutical manufacturers turn to a direct-distribution model to leverage opportunities for cost-effective drug delivery and personalized health management services
Latest:
Rare disease patient supportRare diseases are hard to treat; supporting the patient can be even more challenging
Latest:
Data as a strategic asset in the life sciencesBuilding in the right processes and support for data quality, standards, and governance
